Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In (Q37132598)
Jump to navigation
Jump to search
scientific article published on April 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In |
scientific article published on April 2008 |
Statements
1 reference
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In (English)
1 reference
Scott A Laurie
1 reference
Isabelle Gauthier
1 reference
Andrew Arnold
1 reference
Frances A Shepherd
1 reference
Peter M Ellis
1 reference
Eric Chen
1 reference
Glenwood Goss
1 reference
Jean Powers
1 reference
Wendy Walsh
1 reference
Dongsheng Tu
1 reference
Jane Robertson
1 reference
Thomas A Puchalski
1 reference
Lesley Seymour
1 reference
1 April 2008
1 reference
1 reference
Identifiers
1 reference